TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with suspected or established retinovascular disease who are going to undergo FA as part of their usual clinical evaluation.~2. Patients must be age 13 or above.~3. Patients must be able to speak and understand the English language in order to provide informed consent.~Exclusion Criteria:~1. Any patients who are unwilling to participate or provide informed consent.~2. Any patients who are pregnant at the time of enrollment.~3. Any patients with ocular media opacities which prevent clear evaluation of the fundus by either FA or OCT.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVOCT (Type: None): Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sex - male and female. Men are affected with visual loss more frequently than women, with a male predominance of \~85%. A minimum of 25% of men and 5% of women at risk for LHON experience visual loss.~* Age - 18 years or older. The onset of visual loss typically occurs between the ages of 15 and 35 years, but otherwise classic LHON has been reported in many individuals both younger and older, with a range of age at onset from 2 to 80 years.~* Diagnosis of LHON or a carrier of the gene mutation. Patient must be evaluated by molecular confirmation, with the 11778 and other mutations of Leber's Hereditary Optic Neuropathy stratified in later data analysis.~* Able \& willing to provide informed consent~Exclusion Criteria:~* Has an optic nerve disease other than LHON.~* Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.~* Participation in an investigational trial within 30 days of NIR-LED treatment that involved treatment with any drug that has not received regulatory approval at the time of study entry. (Note: subjects cannot receive another investigational drug while participating in the study during the first 6 months.)~* Major surgery within 28 days prior to participation or major surgery planned during the next 6 months. Major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Symptomatic LHON patients. (Type: EXPERIMENTAL): Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
- Asymptomatic LHON mutation carriers (Type: NO_INTERVENTION): Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for patients who have been in intensive care :~* Diagnosed with Covid-19~* Ventilated in ICU for at least 3 consecutive days~* ICU discharge between 4 and 8 weeks~* Approval received from a physician~* Command of the French language~Inclusion Criteria for patients who have NOT been in intensive care :~* Diagnosed with Covid-19 : positive serological test or positive PCR test following nasopharyngeal swabbing~* Approval received from a physician~* Command of the French language~Exclusion Criteria:~* Taking neuroactive substances that can alter corticospinal excitability~* Patients with co-morbidities leading to significant fatigue: e.g. cancerous pathologies, sleep apnea~* Patients with neurodegenerative or neuromuscular disease~* Contraindication to the application of a magnetic field~* Contraindication to the practice of Magnetic Resonance Imaging~* Participant is pregnant~* Patients with psychiatric disorders~* Paraplegic and hemiplegic patients~* Addictive disorders

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Non-fatigued patients who have been in intensive care units (Type: EXPERIMENTAL): None
- Fatigued patients who have been in intensive care units (Type: EXPERIMENTAL): None
- patients who have not been in intensive care units (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional Differences in Effortful Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Right-handedness~Exclusion Criteria:~* Any clinically significant personal or family history of cardiac problems~* Any current Axis I psychiatric disorder (diagnosis as verified by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV)~* A previous adequate trial with methylphenidate (Ritalin)~* Currently taking any psychoactive medications~* Any clinically significant medical condition~* Any clinically significant neurological problem (seizures, tics, serious head injury)~* Contraindications to MRI (metal objects in body or claustrophobia)~* Currently pregnant or lactating~* Alcohol or substance abuse (current or in the past 2 years)~* Left-handedness or ambidextrous~* Liver or kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Dual Task Paradigm (Type: OTHER): This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Postplacental Mirena IUD Insertion and Estimating Expulsion Rates.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or greater~* obstetric patient in greater Portland, ME area~Exclusion Criteria:~* Evidence of chorioamnionitis (persistent fetal tachycardia, intra-partum fever \>38.0)~* prolonged rupture of membranes (greater than 24 hours)~* intrauterine fetal demise~* use of general anesthesia at time of delivery~* postpartum hemorrhage (\>500ml vaginal, \>1000ml cesarean)~* magnesium administration in labor due to HELLP syndrome or preeclampsia~* preterm delivery.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mirena IUD Placement Immediately Post-delivery (Type: EXPERIMENTAL): Participants enrolling in this study agree to have the IUD placed immediately post-delivery versus waiting the standard 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 years of age or older~* Diagnosis of non-relaxing puborectalis syndrome~Exclusion Criteria:~* Allergy or sensitivity to botulinum toxin~* Pregnancy or plan to become pregnant in the subsequent 6 months after injection~* Undiagnosed ano-rectal mass, lesion, or infection~* Stage II or greater rectocele

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin (Botox) injection (Type: EXPERIMENTAL): All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ASTHMAXcel Emergency Department Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English speakers~* at least 18+ years old with~* physician-diagnosed asthma.~Exclusion Criteria:~* severe cognitive or psychiatric conditions precluding capacity to provide informed consent,~* inability to speak English,~* lacking the technology to access the app.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): All patients will be enrolled in a single arm and download the mobile application ASTHMAxcel ED to their smartphones.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with open-angle glaucoma or ocular hypertension~Exclusion Criteria:~* By Age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Travatan (Type: EXPERIMENTAL): Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
- Cosopt (Type: ACTIVE_COMPARATOR): treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age.~* Histologically documented diagnosis of epithelial carcinoma arising in the ovary, fallopian tube or peritoneum, of any stage or grade at diagnosis. \*Patients must have received initial cytoreductive surgery and chemotherapy with at least one platinum based chemotherapy regimen.~  \*Eligible platinum resistant patients will have failed no more than two additional non platinum cytotoxic regimens for their persistent or recurrent disease.~* Measurable disease.~* Performance status 0, 1, 2 (Eastern Cooperative Oncology Group) .~* Adequate end organ function, defined as the following: total bilirubin \< 1.5 x upper limit of normal (ULN), SGOT and SGPT \< 2.5 x UNL, creatinine \< 1.5 x ULN, ANC \> 1.0 x 10E9/L, platelets \> 100 x 10E9/L.~* Written, voluntary informed consent.~Exclusion Criteria:~* Patient has received any other anticancer treatment within 21 days of first day of study drug dosing and shown recovery of any recent drug-induced neutropenia and thrombocytopenia.~* Patient has another primary malignancy that has required active intervention within 5 years, with the exception of basal cell skin cancer or a cervical carcinoma in situ.~* Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study).~* Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).~* Patients on coumadin-derived anticoagulants.~* Patient with brain metastasis.~* Chronic liver disease, Hep B or C.~* Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.~* Patient received chemotherapy within 3 weeks -unless the disease is rapidly progressing.~* Patient previously received radiotherapy to at least 25 % of the bone marrow.~* Patient had a major surgery within 2 weeks prior to study entry.~* Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.~* Patient is on any drug that may interfere with Gleevec (e.g., Dilantin, Coumadin,or others on the list on page 33-37 of the protocol).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel + Imatinib Mesylate (Gleevec) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pseudophakic~* Retinal Detachment~* Age 18 years and older~* Scheduled for gas bubble repair and laser surgery following retinal detachment~* Willing and able to comply with clinic visits and study related procedures~* Willing and able to sign the informed consent form~Exclusion Criteria:~* Patients under the age of 18.~* Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)~* Active infectious systemic disease~* Active infectious ocular or extraocular disease~* Obstructed nasolacrimal duct in the study eye(s)~* Hypersensitivity to dexamethasone~* Patients being treated with immunomodulating agents in the study eye(s)~* Patients being treated with immunosuppressants and/or oral steroids~* Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intracanalicular Sustained Release Dexamethasone, 0.4 mg (Type: EXPERIMENTAL): Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of post-surgical inflammation and pain associated with ocular surgery.
- topical prednisolone acetate 1%. (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females who weigh at least 9 kg.~* Anticipated to be living or working in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies for at least 4 months.~* Anticipated to have \> 10 hours of contact per week and expected to have direct contact with the interventional study patient.~* The interventional patient is dosed in the interventional study.~Exclusion Criteria:~* Prior treatment with gene therapy utilizing AAV vectors of any serotype.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All participants (Type: None): Household contacts of a DMD patient in an interventional study of fordadistrogene movaparvovec.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Radiation for High Risk Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of urothelial or squamous cell carcinoma of the bladder~* Patients must have undergone cystectomy (total cystectomy, radical cystectomy +/- pelvic lymph node dissection) with no evidence of macroscopic residual disease~* Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0-2~* Patients treated with simple cystectomy with macroscopically negative margins are eligible for this study~* Clinical T-stage (prior to systemic therapy, if applicable) ≥ T3a and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or pathologic T-stage ≥ T3a and/or positive lymph nodes~Exclusion Criteria:~* Patients with metastatic disease outside of the pelvis~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years~* Prior radiation therapy to the pelvis~* Patients with active inflammatory bowel disease~* Severe acute co-morbidity, defined as follows:~  * Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months~ * Transmural myocardial infarction within the last 6 months~ * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration~ * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immunocompromised patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3D conformal radiation therapy (Type: EXPERIMENTAL): Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues